Cytokines (TH1 and TH2) in patients with advanced cervical cancer undergoing neoadjuvant chemoradiation correlation with treatment response

International Journal of Gynecological Cancer

Volumn 19, Issue 7, 2009, Pages 1269-1275

  Sharma, Alpana ^a   Rajappa, Medha ^a   Satyam, Abhigyan ^a   Sharma, Manoj ^b  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b MAULANA AZAD MEDICAL COLLEGE   (India)

Author keywords

Cervical cancer; Cytokines; HPV status; IFN F; IL 10; IL 2; IL 4; Neoadjuvant chemoradiation; Therapeutic response

Indexed keywords

BLEOMYCIN; CISPLATIN; CYTOKINE; FLUOROURACIL; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; ONDANSETRON; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; ARTICLE; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COBALT TELETHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; TH1 CELL; TH2 CELL; TREATMENT RESPONSE; UTERINE CERVIX CARCINOMA; ADJUVANT THERAPY; BLOOD; CARCINOMA; DISEASE COURSE; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; TREATMENT OUTCOME; UTERINE CERVIX TUMOR;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRACHYTHERAPY; CARCINOMA; COMBINED MODALITY THERAPY; CYTOKINES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; TH1 CELLS; TH2 CELLS; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 73449120427     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181a8efcc     Document Type: Article

References (40)

1. Parkin DM, Bray F, Ferlay J, et al. Global Cancer Statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
2. Notani PN. Global variation in cancer incidence and mortality. Curr Sci. 2001;81:465-474.
3. Gupte MD, Ramachandran V, Mutatkar RK. Epidemiological profile of India: historical and contemporary perspectives. J Biosci. 2001;26: 437-464.
4. Yang YC, Wang KL, Su TH, et al. Concurrent cisplatin-based chemoradiation for cervical carcinoma: tumor response, toxicity, and serum cytokine profiles. Cancer Invest. 2006;24:390-395.
5. Mitsuhashi A, Suzuka K, Yamazawa K, et al. Serum vascular endothelial growth factor (VEGF) and VEGF-C levels as tumor markers in patients with cervical carcinoma. Cancer. 2005;103:724-730.
6. Rey A, Klein B, Zagury D, et al. Diminished interleukin-2 activity production in cancer patients bearing solid tumors and its relationship with natural killer cells. Immunol Lett. 1983;6:175-178.
7. Santos LB, Yamada FT, Schienberg A. Monocyte and lymphocyte interaction in patients with advanced cancer. Cancer. 1985;56: 1553-1558.
8. Elsässer-Beile U, von Kleist S, Gallati H. Evaluation of a test system for measuring cytokine production in human whole blood cell cultures. J Immunol Methods. 1991;139:191-195.
9. Clerici M, Shearer GM. The Th1/Th2 hypothesis of HIV infection: new insights. Immunol Today. 1994;15:575-581. (Pubitemid 24353909)
10. Tahara H, Lotze MT. Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer. Gene Ther. 1995;2:96-106.
11. Trinchieri G. Function and clinical use of interleukin-12. Curr Opin Hematol. 1997;4:59-66.
12. Janeway CA Jr, Travers P eds. Immunobiology: the immune system in health and disease. London: Garland, Churchill & Livingstone; 1997.
13. Majewski S, Marczak M, Szmurlo A, et al. Interleukin-12 inhibits angiogenesis induced by human tumor cell lines in vivo. J Invest Dermatol. 1996;106:1114-1118.
14. York IA, Rock KL. Antigen processing and presentation by the class I major histocompatibility complex. Annu Rev Immunol. 1996;14: 369-396.
15. Woodworth CD, Litchti U, Simpson S, et al. Leukoregulin and F-interferon inhibit human papillomavirus type 16 gene transcription in human papillomavirusYimmortalized human cervical cells. Cancer Res. 1992;52:456-463.
16. Mosmann TR, Coffman RL. Two types of mouse helper T-cell clone: implications for immune regulation. Immunol Today. 1987;8:223-226.
17. Moore KW, O'Garra A, de Waal Malefyt R, et al. Interleukin-10. Annu Rev Immunol. 1993;11:165-190.
18. Beissert S, Hosoi J, Grabbe S, et al. IL-10 inhibits tumor antigen presentation by epidermal antigen-presenting cells. J Immunol. 1995;154:1280-1286.
19. Lucey DR, Clerici M, Shearer GM. Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev. 1996;9:533-562.
20. Sharma A, Rajappa M, Saxena A, et al. Cytokine profile in Indian women with cervical intraepithelial neoplasia and cancer cervix. Int J Gynecol Cancer. 2007;17:879-885.
21. Sharma A, Rajappa M, Saxena A, et al. Antioxidant status in advanced cervical cancer patients undergoing neoadjuvant chemoradiation. Br J Biomed Sci. 2007;64:23-27.
22. Druzgal CH, Chen Z, Yeh NT, et al. A pilot study of longitudinal serum cytokine and angiogenesis factor levels as markers of therapeutic response and survival in patients with head and neck squamous cell carcinoma. Head Neck. 2005;27:771-784.
23. International Federation of Gynecology and Obstetrics staging announcement: FIGO staging of gynecologic cancers, cervical and vulva. Int J Gynecol Cancer. 1995;5:319-326.
24. Sharma A, Rajappa M, Menhdiratta PL, et al. Increased levels of interleukin-4, 5 and 10 and decreased levels of interferon-gamma in lymphatic filariasis. Biomed Res. 2005;16:33-39.
25. Jacobs MV, Snijders PJ, van den Brule AJ, et al. A general primer GP5+/6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol. 1997;35:791-795.
26. Lorincz AT, Reid R, Jenson AB, et al. Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet Gynecol. 1992;79:328-337.
27. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. New York, USA: World Health Organization, WHO Publications Centre; 1979.
28. Davis ID. An overview of cancer immunotherapy. Immunol Cell Biol. 2000;78:179-195.
29. Smyth MJ, Godfrey DI. NKT cells and tumor immunityVa double-edged sword. Nat Immunol. 2000;1:459-460.
30. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10:909-915.
31. Tsukui T, Hildesheim A, Schiffman MH, et al. Interleukin 2 production in vitro by peripheral lymphocytes in response to human papillomavirusYderived peptides: correlation with cervical pathology. Cancer Res. 1996;56:3967-3974.
32. Goswami B, Rajappa M, Sharma M, et al. Inflammation: its role and interplay in the development of cancer, with special focus on gynecological malignancies. Int J Gynecol Cancer. 2008;18:591-599.
33. + T cells in the antitumor immune response. J Exp Med. 1998;188:2357-2368.
34. Lin W, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest. 2007;117:1175-1183.
35. Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest. 2007;117:1137-1146.
36. Sundfoør K, Tropé CG, Högberg T, et al. Radiotherapy and neoadjuvant chemotherapy for cervical carcinoma. A randomized multicenter study of sequential cisplatin and 5-fluorouracil and radiotherapy in advanced cervical carcinoma stage 3B and 4A. Cancer. 1996;77:2371-2378.
37. Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340:1144-1153.
38. Tzioras S, Pavlidis N, Paraskevaidis E, et al. Effects of different chemotherapy regimens on survival for advanced cervical cancer: systematic review and meta-analysis. Cancer Treat Rev. 2007;33:24-38.
39. Lukka H, Johnston M. Concurrent cisplatin-based chemotherapy plus radiotherapy for cervical cancer: a meta-analysis. Clin Oncol. 2004;16:160-161.
40. Green J, Kirwan J, Tierney J, et al. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane Database Syst Rev. 2005:CD002225